Literature DB >> 23429704

Quantitative phosphoproteomics reveal mTORC1 activates de novo pyrimidine synthesis.

Aaron M Robitaille1, Stefan Christen, Mitsugu Shimobayashi, Marion Cornu, Luca L Fava, Suzette Moes, Cristina Prescianotto-Baschong, Uwe Sauer, Paul Jenoe, Michael N Hall.   

Abstract

The Ser-Thr kinase mammalian target of rapamycin (mTOR) controls cell growth and metabolism by stimulating glycolysis and synthesis of proteins and lipids. To further understand the central role of mTOR in cell physiology, we used quantitative phosphoproteomics to identify substrates or downstream effectors of the two mTOR complexes. mTOR controlled the phosphorylation of 335 proteins, including CAD (carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase). CAD catalyzes the first three steps in de novo pyrimidine synthesis. mTORC1 indirectly phosphorylated CAD-S1859 through S6 kinase (S6K). CAD-S1859 phosphorylation promoted CAD oligomerization and thereby stimulated de novo synthesis of pyrimidines and progression through S phase of the cell cycle in mammalian cells. Thus, mTORC1 also stimulates the synthesis of nucleotides to control cell proliferation.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23429704     DOI: 10.1126/science.1228771

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  223 in total

Review 1.  mTOR in health and in sickness.

Authors:  Dritan Liko; Michael N Hall
Journal:  J Mol Med (Berl)       Date:  2015-09-22       Impact factor: 4.599

Review 2.  Oncogenes strike a balance between cellular growth and homeostasis.

Authors:  Bo Qiu; M Celeste Simon
Journal:  Semin Cell Dev Biol       Date:  2015-08-13       Impact factor: 7.727

3.  Deamidation Shunts RelA from Mediating Inflammation to Aerobic Glycolysis.

Authors:  Jun Zhao; Mao Tian; Shu Zhang; Alireza Delfarah; Ruoyun Gao; Youliang Rao; Ali Can Savas; Anjie Lu; Larissa Bubb; Xiao Lei; Rosa Moshirian; Wenjie Zhu; Cheng Peng; Taijiao Jiang; Lin Chen; Nicholas A Graham; Pinghui Feng
Journal:  Cell Metab       Date:  2020-04-22       Impact factor: 27.287

Review 4.  Amino acid management in cancer.

Authors:  Zhi-Yang Tsun; Richard Possemato
Journal:  Semin Cell Dev Biol       Date:  2015-08-12       Impact factor: 7.727

Review 5.  mTOR function and therapeutic targeting in breast cancer.

Authors:  Stephen H Hare; Amanda J Harvey
Journal:  Am J Cancer Res       Date:  2017-03-01       Impact factor: 6.166

Review 6.  MenTORing Immunity: mTOR Signaling in the Development and Function of Tissue-Resident Immune Cells.

Authors:  Russell G Jones; Edward J Pearce
Journal:  Immunity       Date:  2017-05-16       Impact factor: 31.745

7.  The adaptor protein p66Shc inhibits mTOR-dependent anabolic metabolism.

Authors:  Mohamed A Soliman; Anas M Abdel Rahman; Dudley W Lamming; Dudley A Lamming; Kivanç Birsoy; Judy Pawling; Maria E Frigolet; Huogen Lu; I George Fantus; Adrian Pasculescu; Yong Zheng; David M Sabatini; James W Dennis; Tony Pawson
Journal:  Sci Signal       Date:  2014-02-18       Impact factor: 8.192

8.  Chromosome 3p loss of heterozygosity is associated with a unique metabolic network in clear cell renal carcinoma.

Authors:  Francesco Gatto; Intawat Nookaew; Jens Nielsen
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-18       Impact factor: 11.205

9.  Emerging role of mTOR in the response to cancer therapeutics.

Authors:  Erika Ilagan; Brendan D Manning
Journal:  Trends Cancer       Date:  2016-05

10.  Targeting of Hematologic Malignancies with PTC299, A Novel Potent Inhibitor of Dihydroorotate Dehydrogenase with Favorable Pharmaceutical Properties.

Authors:  Liangxian Cao; Marla Weetall; Christopher Trotta; Katherine Cintron; Jiyuan Ma; Min Jung Kim; Bansri Furia; Charles Romfo; Jason D Graci; Wencheng Li; Joshua Du; Josephine Sheedy; Jean Hedrick; Nicole Risher; Shirley Yeh; Hongyan Qi; Tamil Arasu; Seongwoo Hwang; William Lennox; Ronald Kong; Janet Petruska; Young-Choon Moon; John Babiak; Thomas W Davis; Allan Jacobson; Neil G Almstead; Art Branstrom; Joseph M Colacino; Stuart W Peltz
Journal:  Mol Cancer Ther       Date:  2018-10-23       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.